다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of visualized experiments : JoVE, no.129, 2017년, pp.56596 -
Madasamy, Shanmugavel (Plaxgen Inc) , Liu, David (Plaxgen Inc) , Lundry, Jason (Plaxgen Inc) , Alderete, Benjamin (Millipore Sigma) , Kong, Raymond (Millipore Sigma) , Robinson, J. Paul (Cytometry Laboratories, Purdue University) , Wu, Alan H.B. (Plaxgen Inc) , Amento, Edward P. (Molecular Medicine Research Institute)
AI-Helper
Treatment of dyslipidemia patients with lipid-lowering drugs leads to a significant reduction in low-density lipoproteins (LDL) level and a low to moderate level of increase in high-density lipoprotein (HDL) cholesterol in plasma. However, a possible role of these drugs in altering morphology and di...
Pahan K Lipid-lowering drugs Cell Mol Life Sci 2006 63 1165 1178 16568248
Laforest L Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs Arch Cardiovasc Dis 2009 102 43 50 19233108
Roberts WC Preventing and arresting coronary atherosclerosis Am Heart J 1995 130 580 600 7661078
Goldstein JL Brown MS A century of cholesterol and coronaries: from plaques to genes to statins Cell 2015 16 161 172
Drexel H Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients? Fundam Clin Pharmacol 2009 23 687 692 19682084
Camelia S Anca S Statins: Mechanism of action and effects J.Cell.Mol.Med 2001 5 378 387 12067471
Schaefer EJ Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects Am J Cardiol 2004 93 31 39 14697462
Meyers CD Kamanna VS Kashyap ML Niacin therapy in atherosclerosis Curr Opin in Lipid 2004 15 659 665
Phan BA Dayspringm TD Toth PP Ezetimibe therapy: mechanism of action and clinical update Vasc Health Risk Mana 2012 8 415 427
Leitersdorf E Fruchart JC Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 1998 98 2088 2093 9808609
Backes J Anzalone D Hilleman D Catini J The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia Lipids Health Dis 2016 15 118 27444154
Davidson MH Clinical Significance of Statin Pleiotropic Effects Hypotheses Versus Evidence Circulation 2005 111 2280 2281 15883224
Chinetti-Gbaguidi G Fruchart JC Staels B Pleiotropic effects of fibrates Curr Atheroscler Rep 2005 7 396 401 16105484
McTaggart F Jones P Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit CardiovascDrugs Ther 2008 22 321 338
Quehenberger O The Human Plasma Lipidome N Engl J Med 2011 365 1812 1823 22070478
Lund-Katz S Mechanisms responsible for the compositional heterogeneity of nascent high density lipoprotein J. Biol Chem 2013 288 23150 23160 23836906
Krauss RM Lipoprotein subfractions and cardiovascular disease risk Curr Opin Lipidol 2010 21 305 311 20531184
Krauss RM Burke DJ Identification of multiple subclasses of plasma low density lipoproteins in normal humans J Lipid Res 1982 23 97 104 7057116
Rosenson RS HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular Events Clinic Chemi 2011 57 392 410
Madasamy S Plaque array method and proteomics-based identification of biomarkers from Alzheimer's disease serum Clin Chim Acta 2015 441 79 85 25532947
Madasamy S Nonenzymatic Mechanism of Statins in Modulating Cholesterol Particles Formation Am J Cardiol 2016 118 1187 1191 27614849
Peter OK Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity Am J Cardiol 2002 90 30 47
Weissglas-Volkov D Pajukanta P Genetic causes of high and low serum HDL-cholesterol J Lipid Res 2010 51 2032 2057 20421590
Abela GS Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization Am J Cardiol 2011 107 1710 1717 21507364
Nidorf SM Eikelboom JW Thompson PL Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease Cardiovasc Pharmacol Ther 2014 19 45 52
Thacker SG Zarzour A Chen High density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation Immunol 2016 149 306 319
Kim SH Lee ES Lee JY Multiplex coherent anti-stokes Raman Spectroscopy images intact atheromatous lesions and concomitantly identifies distinct chemical profiles of atherosclerotic lipids Circ Res 2010 106 1332 1341 20299664
Lim RS Suhalim JL Miyazaki-Anzai S Identification of cholesterol crystals in plaques of atherosclerotic mice using hyperspectral CARS imaging J Lipid Res 2011 52 2177 2186 21949051
Rothblat GH Phillips MC High-density lipoprotein heterogeneity and function in reverse cholesterol transport Curr Opin Lipidol 2011 21 229 238
Kontush A HDL particle number and size as predictors of cardiovascular disease Front in Pharmacol 2015
Karathanasis SK Freeman LA Gordon SM Remaley AT The changing face of HDL and the best way to measure it Clin. Chem 2017 63 196 210 27879324
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.